{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:08:06Z","timestamp":1762520886452},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T00:00:00Z","timestamp":1068768000000},"content-version":"vor","delay-in-days":2357,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:sec><jats:title>Aim:<\/jats:title><jats:p>Effective anti\u2010<jats:italic>Helicobacter pylori<\/jats:italic> therapies with few side\u2010effects are needed. We studied the effectiveness of a low\u2010dose combination of metronidazole, amoxycillin and omeprazole for treatment of ulcer patients in Seoul, Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Patients with gastric or duodenal ulcer received metronidazole (125\u2003mg b.d.), amoxycillin (500\u2003mg b.d.) and omeprazole (20\u2003mg at bedtime) for 2 weeks. Endoscopic examinations were performed before treatment and at least 6 weeks after completion of antimicrobial therapy. <jats:italic>H. pylori<\/jats:italic> status was confirmed by histological examination of two gastric biopsies using the Genta stain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Seventy\u2010nine patients (64 men, 15 women, mean age 46 years) with peptic ulcer were enrolled. <jats:italic>H. pylori<\/jats:italic> infection was cured in 56 (71%, 95% CI: 60\u201381%). The cure rate in non\u2010smokers was significantly higher than in smokers (88% vs. 65%, <jats:italic>P<\/jats:italic>=0.035). Twelve pre\u2010treatment isolates were available and metronidazole resistance was noted in all; <jats:italic>H. pylori<\/jats:italic> infection was cured in 10. Thirty\u2010six patients cured of <jats:italic>H. pylori<\/jats:italic> have been followed for 1 year (mean of 361 days) and 2 cases became reinfected (5.5%, 95% CI: 1\u201318%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The low\u2010dose combination of metronidazole, amoxycillin and omeprazole was effective even in the face of metronidazole resistance. Recurrence of <jats:italic>H. pylori<\/jats:italic> infection is infrequent even in countries with a high prevalence of <jats:italic>H. pylori<\/jats:italic> infection.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1997.00173.x","type":"journal-article","created":{"date-parts":[[2003,11,14]],"date-time":"2003-11-14T11:46:44Z","timestamp":1068810404000},"page":"523-527","source":"Crossref","is-referenced-by-count":12,"title":["Successful low\u2010dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole\u2010resistant <i>Helicobacter pylori<\/i>"],"prefix":"10.1111","volume":"11","author":[{"given":"T.","family":"Breuer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. G.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. E.","family":"Gurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. P.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Osato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"Genta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Y.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,14]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"B\u00f6rschGM&GrahamDYHelicobacter pylori.In: Collen MJ Benjamin SB eds. Pharmacology of Peptic Ulcer Disease. Handbook of Experimental Pharmacology Vol. 99 Berlin: Springer\u2010Verlag 1991: 107\u201348."},{"key":"e_1_2_1_3_2","unstructured":"GrahamDY&B\u00f6rschGMAThe who's and when's of therapy forHelicobacter pylori. Am J Gastroenterol1990;11:1552\u20135."},{"key":"e_1_2_1_4_2","unstructured":"Van Der HulstRWM KellerJJ RauwsEA TytgatGNJTreatment ofHelicobacter pyloriinfection in humans: a review of the world literature. Helicobacter1996;11:6\u201319."},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","unstructured":"BellGD BateCM AxonATR et al. Addition of metronidazole to omeprazole\/amoxycillin dual therapy increases the rate ofHelicobacter pylorieradication: a double\u2010blind randomized trial. Aliment Pharmacol Ther1995;11:513\u201320.","DOI":"10.1111\/j.1365-2036.1995.tb00414.x"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","unstructured":"GrahamDY LewGM MalatyHM et al.Factors influencing the eradication ofHelicobacter pyloriwith triple therapy. Gastroenterology1992;11:493\u20136.","DOI":"10.1016\/0016-5085(92)90095-G"},{"key":"e_1_2_1_7_2","unstructured":"GrahamDYDeterminants of antimicrobial effectiveness inH. pylorigastritis. In: Hunt RH Tytgat GNJ eds.Helicobacter pylori.Basic Mechanisms to Clinical Cure Dordrecht: Kluwer Academic Publishers 1994: 531\u20137."},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","unstructured":"PenstonJGHelicobacter pylorieradication\u2014understandable caution but no excuse for inertia. Aliment Pharmacol Ther1994;11:369\u201389.","DOI":"10.1111\/j.1365-2036.1994.tb00304.x"},{"key":"e_1_2_1_9_2","unstructured":"ReddyR OsatoM GutierrezO KimJG GrahamDY. Metronidazole resistance is high in Korea and Columbia and appears to be rapidly increasing in the US. Gastroenterology1996;11: A238 (Abstract)."},{"key":"e_1_2_1_10_2","unstructured":"XiaHX BuckleyM HydeD KeaneCT O'MorainCAEffects of antibiotic resistance on clarithromycin combined triple therapy forHelicobacter pylori. Gut1995;11: A55(Abstract)"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","unstructured":"YousfiMM El\u2010ZimaityHM Al\u2010AssiMT ColeRA GentaRM GrahamDYMetronidazole omeprazole and clarithromycin: an effective combination therapy forHelicobacter pyloriinfection. Aliment Pharmacol Ther1995;11:209\u201312.","DOI":"10.1111\/j.1365-2036.1995.tb00374.x"},{"key":"e_1_2_1_12_2","unstructured":"MoayyediP SahayP TompkinsDS AxonATEfficacy and optimum dose of omeprazole in a new 1\u2010week triple therapy regimen to eradicateHelicobacter pylori. Eur J Gastroenterol Hepatol1995;11:835\u2013840."},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","unstructured":"XiaH DawM SantS BeattieS KeaneC O'MorainCClinical efficacy of triple therapy inHelicobacter pylori\u2010associated duodenal ulcer. Eur J Gastroenterol Hepatol1993;11:141\u20134.","DOI":"10.1097\/00042737-199303000-00004"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","unstructured":"De BoerW DriessenW JanszA TytgatGEffect of acid suppression on efficacy of treatment forHelicobacter pyloriinfection. Lancet1995;11:817\u201320.","DOI":"10.1016\/S0140-6736(95)92962-2"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","unstructured":"BorodyT AndrewsP FracchiaG BrandlS ShortisNP BaeHOmeprazole enhances efficacy of triple therapy in eradicatingHelicobacter pylori. Gut1995;11:477\u201381.","DOI":"10.1136\/gut.37.4.477"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","unstructured":"GentaRM RobasonGO GrahamDYSimultaneous visualization ofHelicobacter pyloriand gastric morphology: a new stain. Hum Pathol1994;11:221\u20136.","DOI":"10.1016\/0046-8177(94)90191-0"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","unstructured":"HachemCY ClarridgeJE ReddyR et al.Antimicrobial susceptibility testing ofHelicobacter pylori. Comparison of E\u2010Test broth microdilution and disk diffusion for ampicillin clarithromycin and metronidazole. Diagn Microbiol Infect Dis1996;11:37\u201341.","DOI":"10.1016\/0732-8893(95)00252-9"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","unstructured":"FaganTQuickbasic program for exact and mid\u2010P confidence intervals for a binomial proportion. Comput Biol Med1996;11:263\u20137.","DOI":"10.1016\/0010-4825(96)00006-6"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","unstructured":"NIH Consensus Conference.Helicobacter pyloriin peptic ulcer disease. NIH Consensus Development Panel onHelicobacter pyloriin Peptic Ulcer Disease. J Am Med Assoc1994;11:65\u20139.","DOI":"10.1001\/jama.272.1.65"},{"key":"e_1_2_1_20_2","unstructured":"PeuraDA&GrahamDYHelicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol1994;11:1137\u20139."},{"key":"e_1_2_1_21_2","unstructured":"GrahamDYA reliable cure forHelicobacter pyloriinfection? Gut1995;11:154\u20136."},{"key":"e_1_2_1_22_2","unstructured":"FerrariAP GeoczeS LanzoniVP ToledoMR TrabulsiLR VilelaMPUse of ampicillin plus ranitidine forHelicobacter pylorigastritis. Braz J Med Biol Res1991;11:567\u201372."},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","unstructured":"LouwJA LuckeW JaskiewiczK LastovicaAJ WinterTA MarksINHelicobacter pylorieradication in the African setting with special reference to reinfection and duodenal ulcer recurrence. Gut1995;11:544\u20137.","DOI":"10.1136\/gut.36.4.544"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","unstructured":"LouwJA ZakJ LuckeW et al.Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicatingHelicobacter pyloriand reducing duodenal ulcer relapse rates. Scand J Gastroenterol1992;11(Suppl.):28\u201331.","DOI":"10.3109\/00365529209093227"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","unstructured":"HoskingSW LingTK YungMY et al. Randomised controlled trial of short term treatment to eradicateHelicobacter pyloriin patients with duodenal ulcer. Br Med J1992;11:502\u20134.","DOI":"10.1136\/bmj.305.6852.502"},{"key":"e_1_2_1_26_2","unstructured":"SungJ LeungV ChungS et al.Triple therapy with sucralfate tetracycline and metronidazole forHelicobacter pylori\u2010associated duodenal ulcers. Am J Gastroenterol1995;11:1424\u20137."},{"key":"e_1_2_1_27_2","unstructured":"KimuraK IdoK SaifukuK et al.A 1\u2010h topical therapy for the treatment ofHelicobacter pyloriinfection. Am J Gastroenterol1995;11:60\u20133."},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","unstructured":"SungJ ChungS LingT et al.Antibacterial treatment of gastric ulcers associated withHelicobacter pylori. N Engl J Med1995;11:139\u201342.","DOI":"10.1056\/NEJM199501193320302"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","unstructured":"LabenzJ LeverkusF BorschGOmeprazole plus amoxicillin for cure ofHelicobacter pyloriinfection. Factors influencing the treatment success. Scand J Gastroenterol1994;11:1070\u20135.","DOI":"10.3109\/00365529409094890"},{"key":"e_1_2_1_30_2","unstructured":"GrahamDY De BoerWA TytgatGNChoosing the best anti\u2010Helicobacter pyloritherapy: effect of antimicrobial resistance. Am J Gastroenterol1996;11:1072\u20136."},{"key":"e_1_2_1_31_2","unstructured":"UngeP GadA ErikssonK et al.Amoxycillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol1993;11:325\u201331."},{"key":"e_1_2_1_32_2","doi-asserted-by":"crossref","unstructured":"BardhanKD GrahamDY HuntRH O'MorainCA. Effects of smoking on cure ofH. pyloriinfection and duodenal ulcer recurrence in patients treated with clarithromicin and omeprazole. Helicobacter1997 in press.","DOI":"10.1111\/j.1523-5378.1997.tb00053.x"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","unstructured":"DixonJSHelicobacter pylorieradication: unravelling the facts. Scand J Gastroenterol1995;11(Suppl.):48\u201362.","DOI":"10.3109\/00365529509090302"},{"key":"e_1_2_1_34_2","unstructured":"BorodyTJ ColeP NoonanS et al.Recurrence of duodenal ulcer andCampylobacterpyloriinfection after eradication. Med J Aust1989;11:431\u20135."},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","unstructured":"CoelhoLG PassosMC ChaussonY et al.Duodenal ulcer and eradication ofHelicobacter pyloriin a developing country. An 18\u2010month follow\u2010up study. Scand J Gastroenterol1992;11:362\u20136.","DOI":"10.3109\/00365529209000088"},{"key":"e_1_2_1_36_2","unstructured":"CulterAF&SchubertTTLong\u2010termHelicobacter pylorirecurrence after successful eradication with triple therapy. Am J Gastroenterol1993;11:1359\u201361."},{"key":"e_1_2_1_37_2","unstructured":"GrahamDY&GentaRM. Reinfection withH. pylori. In: Hunt RH Tytgat GNJ eds.Helicobacter pylori. Basic mechanisms to clinical cure Dordrecht: Kluwer Academic Publishers 1994: 113\u201320."},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","unstructured":"HopkinsRJ GirardiLS TurneyEARelationship betweenHelicobacter pylorieradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology1996;11:1244\u201352.","DOI":"10.1053\/gast.1996.v110.pm8613015"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1997.00173.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1997.00173.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T13:54:19Z","timestamp":1698414859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1997.00173.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1046\/j.1365-2036.1997.00173.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1997.00173.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}